Antimicrobial prophylaxis for primary immunodeficiencies

Current Opinion in Allergy and Clinical Immunology

Volumn 9, Issue 6, 2009, Pages 525-530

  Freeman, Alexandra F ^a   Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibiotic prophylaxis; Humoral defects; Hyper IgE syndrome; Neutrophil defects; Primary immunodeficiencies

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; GAMMA INTERFERON; I KAPPA B KINASE GAMMA; IMMUNOMODULATING AGENT; ITRACONAZOLE; POSACONAZOLE; QUINOLONE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BONE MARROW TRANSPLANTATION; BRONCHIECTASIS; CHRONIC GRANULOMATOUS DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CYSTIC FIBROSIS; DESENSITIZATION; DIGEORGE SYNDROME; DISEASE ASSOCIATION; EAR INFECTION; EVIDENCE BASED PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE ADHESION DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY 1; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOCUTANEOUS CANDIDIASIS; NEUTROPENIA; NOCARDIA; ONYCHOMYCOSIS; PREMATURITY; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; NEUTROPHILS; ORGAN TRANSPLANTATION; PREGNANCY;

EID: 70350751650     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328332be33     Document Type: Review

References (38)

1. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomme.
2. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic fever, endocarditis, and Kawasaki disease committee, Council on Cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation 2007; 116:1736-1754.
3. Mattoo TK. Are prophylactic antibiotics indicated after a urinary tract infection? Curr Opin Pediatrics 2009; 21:203-206.
4. Giebink GS. Otitis media prevention: nonvaccine prophylaxis. Vaccine 2001; 19:S129-S133.
5. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pedatrics 2008; 121:703-710.
6. Gafter-Gvili A, Fraser A, Paul M, et al. Antimicrobial prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005; 4:1-59.
7. Yong P, Orange J. Use of prophylactic antibiotics and adjunctive therapies in primary immunodeficiency diseases. Abstract, FOCIS, published in Clinical Immunology 2007; 123:S39-S40.
8. Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease: report of a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-169.
9. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140:255-266.
10. Margolis DH, Melnick DA, Alling DW, Gallin JI. Trimethoprim- sulfamethoxasole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723-726.
11. Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with trimethoprim-sulfamethoxasole in patients with chronic granulomatous disease. J Pediatrics 1983; 1-3:127-130.
12. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous diseases. N Engl J Med 2003; 348:2416-2422.
13. Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008; 21:409-414.
14. Etzioni A. Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options. Adv Exp Med Biol 2007; 601:51-60.
15. Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004; 113:620-626.
16. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Ann Rev Immunol 2009; 27:199-227.
17. Bonilla FA, Berstein L, Khan DA, Ballas ZK, et al. Practice parameters for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1-S63.
18. Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical Immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2008; 155:147-155.
19. Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otits media in children. Cochrane Database Syst Rev 2006; 4:CD004401.
20. Liston TE, Foshee WS, Pierson WD. Sulfisoxazole chemoprophylaxis for frequent otitis media. Pediatrics 1983; 71:524-530.
21. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respiratory Med 2008; 102:1494-1496.
22. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4:117-122.
23. Hagerman JK, Hancock KE, Klepser ME. Aerosolized antibiotics: a critical appraisal of their use. Exp Opin Drug Deliv 2006; 3:71-86.
24. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in noncystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39-44.
25. Rubin BK. Aerosolized antibiotics for noncystic fibrosis bronchiectasis. J Aerosol Med Pulmon Drug Deliv 2008; 21:71-76.
26. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420-1426.
27. Puck JM. Severe combined immunodeficiency: new advances in diagnosis and treatment. Immunol Res 2007; 38:64-67.
28. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, diGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007; 2007:1443-1452.
29. Perez EE, Bokszczanin A, McDonald-McGinn D, et al. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (diGeorge/velocardiofacial syndrome). Pediatrics 2003; 112:e325.
30. Freeman AF, Holland SM. The Hyper-IgE syndromes. Immunol Allergy Clin N Am 2008; 28:277-291.
31. Freeman AF, Kleiner DE, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007; 119:1234-1240.
32. Hilliard T, Edwards S, Buchdahl, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibrosis 2005; 4:215-220.
33. Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respiratory Med 2004; 98:915-923.
34. Husain S, Paterson Dl, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008-3016. (Pubitemid 44777932)
35. Borro J, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40:3090-3093.
36. Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect 2006; 8:1157-1166.
37. Ward CM, Jyonouchi H, Kotenko SV, Smirnov SV, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon-alpha 2B in a patient with complete interferon-gamma R1 deficiency. Eur J Pediatrics 2007; 166:981-985.
38. Orange JS, Jain A, Ballas ZK, et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004; 113:725-733.